Johnson & Johnson $JNJ Stock Holdings Trimmed by Baugh & Associates LLC

Key Points

• Baugh & Associates LLC has reduced its holdings in Johnson & Johnson by 5.3%, now owning 30,354 shares, making it the 22nd largest position in their portfolio.
• Johnson & Johnson reported a quarterly revenue of $23.74 billion, beating analysts' estimates and showing a 5.8% increase compared to the same quarter last year.
• The company recently declared a quarterly dividend of $1.30, resulting in an annualized dividend yield of 3.0% and a payout ratio of 55.61%.

Baugh & Associates LLC trimmed its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,354 shares of the company's stock after selling 1,713 shares during the period. Johnson & Johnson comprises approximately 2.2% of Baugh & Associates LLC's holdings, making the stock its 22nd largest holding. Baugh & Associates LLC's holdings in Johnson & Johnson were worth $4,299,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Highline Wealth Partners LLC raised its holdings in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after buying an additional 86 shares during the period. Stone House Investment Management LLC bought a new stake in shares of Johnson & Johnson in the first quarter valued at about $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter worth about $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the 1st quarter worth about $49,000. Finally, Capital A Wealth Management LLC acquired a new position in Johnson & Johnson in the fourth quarter worth $50,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Bank of America lifted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Royal Bank Of Canada upped their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research report on Thursday, July 17th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Finally, Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $178.80.

Johnson & Johnson Stock Down 1.1%

JNJ stock traded down $1.97 during trading on Monday, reaching $174.22. 7,186,784 shares of the company traded hands, compared to its average volume of 7,799,981. The company has a market capitalization of $419.58 billion, a price-to-earnings ratio of 18.63, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The business has a 50 day simple moving average of $173.14 and a 200 day simple moving average of $161.69. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's quarterly revenue was up 5.8% on a year-over-year basis. During the same period in the previous year, the firm earned $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. The ex-dividend date of this dividend was Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.